John K. Scott Jr. - Nov 27, 2023 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB)

Role
Director, 10%+ Owner
Signature
Gioia Gentile on behalf of John K. Scott, Jr., by power of attorney
Stock symbol
NAVB
Transactions as of
Nov 27, 2023
Transactions value $
$4,028,900
Form type
4
Date filed
12/5/2023, 06:26 PM
Previous filing
Jun 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAVB Series G Redeemable Preferred Stock Other -2.27K -100% 0 Nov 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAVB Series I Convertible Preferred Stock Other -$2.4M -2.4K -100% $1,000.00* 0 Nov 27, 2023 Common Stock 15M $0.16 Direct F1, F2
transaction NAVB Series J Convertible Preffered Stock Other $6.43M +64.3K $100.00* 64.3K Nov 27, 2023 Common Stock 61.8M $0.10 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Navidea entered into a Loan and Exchange Agreement with the Reporting Person, pursuant to which he surrendered 2,270 shares of Series G Preferred Stock, par value $.001 per share plus accrued and unpaid dividends thereon, and 2,400 shares of Series I Preferred Stock, par value $.001 per share, and other consideration, in exchange for 64,289 shares of Series J Preferred Stock, par value $.001.
F2 Series J Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.

Remarks:

Exhibit 24: John K. Scott, Jr. Power of Attorney